In vivo molecular targeted radiotherapy

Biomedical Imaging and Intervention Journal

Volumn 1, Issue 2, 2005, Pages

  Perkins, Alan C ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Nuclear medicine therapy; Radionuclide therapy; Targeted therapy

Indexed keywords

EID: 57049155499     PISSN: None     EISSN: 18235530     Source Type: Journal    
DOI: 10.2349/biij.1.2.e9     Document Type: Review

References (39)

1. Proescher F. The intravenous injection of soluble radium salts in man. Radium 1914; 2:61-64.
2. Wheldon TE, Mairs RJ, Rampling RP, et al. Modelling the enhancement of fractionated radiotherapy by gene transfer to sensitize tumour cells to radiation. Radiother Oncol 1998; 48:5-13.
3. Thierens HM, Monsieurs MA, Bacher K. Patient dosimetry in radionuclide therapy: the whys and the wherefores. Nucl Med Commun 2005; 26:593-9.
4. Schubiger PA, Alberto R, Smith A. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 1996; 7:165-79.
5. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 15:3039-51.
6. Dvorak HF, Nagy JA, Dvorak JT et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133:95-109.
7. Jain RK, Gerlowski LE. Extravascular transport in normal and tumor tissue. Crit Rev Oncol Hematol 1986; 5:115-170.
8. Maeda H. The tumor blood vessel as an ideal target for macromolecular anticancer agents. J Control Release 1992; 19:315-324.
9. Blankenship DR, Chin E, Terris DJ. Contemporary management of thyroid cancer. Am J Otolaryngol 2005; 26:249-60.
10. Schneider P, Farahati J, Reiners C. Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J Nucl Med 2005; 46 Suppl 1:48S-54S.
11. Li S, Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 2005; 5:139-48.
12. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 2005; 19:145-63.
13. Baath M, Kolbeck KG, Danielsson R. Somatostatin receptor scintigraphy with 99mTc-Depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiol 2004; 45:833-9.
14. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 Suppl 1:67S-75S.
15. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23(12):2754-2762.
16. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46 Suppl 1:62S-6S.
17. Crippa F, Seregni E, Agresti R, et al. Bone scintigraphy in breast cancer: a ten years follow up study. J Nucl Biol Med 1993; 37:57-61.
18. Quinn DL, Ostrow LB, Poerter DK, et al. Staging of non-small cell bronchogenic carcinoma: relationship of the clinical evaluation to organ scans. Chest 1986; 89:270-275.
19. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005; 6: 392-400.
20. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46 Suppl 1:38S-47S.
21. Liepe K, Kropp J, Runge R, et al. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 2003; 89:625-629.
22. Deland F, Goldenberg DM. Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies. Semin Nucl Med 1985; 15:2-11.
23. Divigi CR and Larson SM. Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin Nucl Med 1989; 19:252-261.
24. Larson, S.M. Radioimmunology. Imaging and therapy Cancer 1991; 67: 1253-1260.
25. Bischof-Delaloye, A, Delaloye B. Tumour targeting with monoclonal antibodies. Semin Nucl Med 1995; 25:144-164.
26. Owens RJ, Young RJ. The genetic engineering of monoclonal antibodies. J Immunol Methods 1994; 168: 149-165.
27. Goetz C, Rachinger W, Poepperl G, et al. Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir Suppl 2003; 88:69-75.
28. Hughes OD, Bishop MC, Perkins AC, et al. Targeting superficial bladder cancer by the intravesical administration of Copper-67-labelled anti-MUC1 mucin monoclonal antibody. J Clin Oncol 2000; 18:363-370.
29. Murray A, Simms MS, Scholfield DP, et al. Production and characterisation of Re-188-C595 antibody for redioimmunotherapy of transitional cell bladder cancer. J Nucl Med 2001; 42:726-732.
30. Anderson DR, Grillo-Lopez A, Varns C, et al. Targeted anticancer therapy using rituximab, a chimeric anti-CD20 antibody (IDECC2B8) in the treatment of non-Hodgkin's B-cell lymphoma Biochem Soc Trans 1997; 25:705-708
31. Illidge TM, Johnson PWM. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematology 2000; 108: 679-688.
32. Borghaei RJ and Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibrtumomab tiuxetan (Zevalin). Seminars Nucl Med 2004; 34: 4-9.
33. Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Semin Oncol 2005; 32:S36-43.
34. Schuetze SM. Imaging and response in soft tissue sarcomas. Hematol Oncol Clin North Am 2005; 19:471-87.
35. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999; 45:1628-1650.
36. Guhlke S., Famulok M., Biersack HJ, et al. A novel class of radiopharmaceutical with diagnostic and therapeutic potential. Eur J Nucl Med Mol Imaging 2003; 30:1441-1443.
37. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005; 46 Suppl 1:199S-204S.
38. Allen BJ, Raja C, Rizvi S, et al. Targeted alpha therapy for cancer. Phys Med Biol 2004; 49:3703-12.
39. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-9.